Peng Dao-Quan, Wu Zhiping, Brubaker Gregory, Zheng Lemin, Settle Megan, Gross Eitan, Kinter Michael, Hazen Stanley L, Smith Jonathan D
Department of Cell Biology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
J Biol Chem. 2005 Oct 7;280(40):33775-84. doi: 10.1074/jbc.M504092200. Epub 2005 Aug 8.
Apolipoprotein A-I (apoAI), the major protein of high density lipoprotein, plays an important role in reverse cholesterol transport via its activity as an ABCA1-dependent acceptor of cellular cholesterol. We reported recently that myeloperoxidase (MPO) modification of apoAI inhibits its ABCA1-dependent cholesterol acceptor activity (Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. (2004) J. Clin. Invest. 114, 529-541). We also reported that MPO-mediated chlorination preferentially modifies two of the seven tyrosines in apoAI, and loss of parent peptides containing these residues dose-dependently correlates with loss in ABCA1-mediated cholesterol acceptor activity (Zheng, L., Settle, M., Brubaker, G., Schmitt, D., Hazen, S. L., Smith, J. D., and Kinter, M. (2005) J. Biol. Chem. 280, 38-47). To determine whether oxidative modification of apoA-I tyrosine residues was responsible for the MPO-mediated inactivation of cholesterol acceptor activity, we made recombinant apoAI with site-specific substitutions of all seven tyrosine residues to phenylalanine. ApoAI and the tyrosine-free apoAI were equally susceptible to dose-dependent MPO-mediated loss of ABCA1-dependent cholesterol acceptor activity, as well as lipid binding activity. MPO modification altered the migration of apoAI on SDS gels and decreased its alpha-helix content. MPO-induced modification also targeted apoAI tryptophan and lysine residues. Specifically, we detected apoAI tryptophan oxidation to mono- and dihydroxytryptophan and apoAI lysine modification to chlorolysine and 2-aminoadipic acid. Thus, tyrosine modification of apoAI is not required for its MPO-mediated inhibition of cholesterol acceptor activity.
载脂蛋白A-I(apoAI)是高密度脂蛋白的主要蛋白质,通过作为ABCA1依赖性细胞胆固醇受体的活性,在逆向胆固醇转运中发挥重要作用。我们最近报道,apoAI的髓过氧化物酶(MPO)修饰会抑制其ABCA1依赖性胆固醇受体活性(郑,L.,努库纳,B.,布伦南,M.L.,孙,M.,古尔马斯特,M.,塞特尔,M.,施密特,D.,傅,X.,汤姆森,L.,福克斯,P.L.,伊施罗普洛斯,H.,史密斯,J.D.,金特,M.,和哈森,S.L.(2004年)《临床研究杂志》114,529 - 541)。我们还报道,MPO介导的氯化优先修饰apoAI七个酪氨酸中的两个,含有这些残基的亲本肽的丢失与ABCA1介导的胆固醇受体活性的丧失呈剂量依赖性相关(郑,L.,塞特尔,M.,布鲁贝克,G.,施密特,D.,哈森,S.L.,史密斯,J.D.,和金特,M.(2005年)《生物化学杂志》280,38 - 47)。为了确定apoA-I酪氨酸残基的氧化修饰是否是MPO介导的胆固醇受体活性失活的原因,我们制备了将所有七个酪氨酸残基位点特异性替换为苯丙氨酸的重组apoAI。apoAI和无酪氨酸的apoAI同样易受剂量依赖性MPO介导的ABCA1依赖性胆固醇受体活性丧失以及脂质结合活性丧失的影响。MPO修饰改变了apoAI在SDS凝胶上的迁移,并降低了其α-螺旋含量。MPO诱导的修饰还靶向apoAI的色氨酸和赖氨酸残基。具体而言,我们检测到apoAI色氨酸氧化为单羟基和二羟基色氨酸,以及apoAI赖氨酸修饰为氯赖氨酸和2-氨基己二酸。因此,apoAI的酪氨酸修饰不是其MPO介导的胆固醇受体活性抑制所必需的。